Condition

Hepatitis C Infection

ClinicalTrials.gov condition label

Clinical trials11

Recruiting0

Common interventions14

Lead sponsors shown10

Clinical trials

11 shown

Evaluation of HCV Care and Treatment for HIV-HCV Co-infected Patients in Decentralised Areas in VietnamNCT05506475 · 2024-05-01

Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus InfectionNCT04042740 · 2019-11-20

A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive IndividualsNCT02568332 · 2015-07-21

Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related QualityNCT02427204 · 2015-06-01

A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in CombinationNCT02362217 · 2014-10-01

HCV-HIV Co-infected Patient Cohort in ThailandNCT02247440 · 2014-08-01

Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot StudyNCT02220868 · 2014-07-01

Study on Immunopathogenesis in HIV and Hepatitis C CoinfectionNCT01296529 · 2011-07-01

A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment FailuresNCT01185028 · 2010-08-01

Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected SubjectsNCT00991289 · 2010-01-01

An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug UsersNCT00841477 · 2004-01-01

Common interventions

AdCh3NSmut1BIOLOGICAL2 MVA-NSmutBIOLOGICAL2 Blood samplesPROCEDURE1 ChAdV63.HIVconsvBIOLOGICAL1 Glecaprevir/Pibrentasvir (G/P)DRUG1 HBV Vaccination Self-Efficacy InterventionBEHAVIORAL1 hepatitis B vaccine 3 dose schedule (0,1,2 month)BIOLOGICAL1 MVA.HIVconsvBIOLOGICAL1 Nitazoxanide (NTZ)DRUG1 Nitazoxanide With Pegylated Interferon And RibavirinDRUG1 Peg-interferon + ribavirin under HIV physician supervisionDRUG1 Pegylated interferon alfa-2a (PEG)DRUG1 Ribavirin (RBV)DRUG1 Sofosbuvir, Ribavirin, and StribildDRUG1

Leading sponsors

University of Oxford2 Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections1 Icahn School of Medicine at Mount Sinai1 Institut de Recherche pour le Developpement1 Institut Pasteur1 National Institute of Allergy and Infectious Diseases (NIAID)1 National Institute on Drug Abuse (NIDA)1 National Institutes of Health Clinical Center (CC)1 Rush University Medical Center1 Saint Michael's Medical Center1

Trial status mix

COMPLETED10

UNKNOWN1

Phase mix

PHASE13

PHASE23

PHASE42

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.